Lilly commits more than $1 billion to Indian contract manufacturing

Eli Lilly said on October 6 that it will invest more than $1 billion in India over the coming years to expand manufacturing and supply through local drugmakers ^[1]. The company does not currently operate its own manufacturing plant in India, so the investment will flow through contract manufacturers that make injectable drugs and other complex medicines for larger pharmaceutical firms ^[1].

Patrik Jonsson, president of Lilly International, said the company is "making significant investments to increase manufacturing and medicine supply capacity around the world," and described India as a hub for building manufacturing capability within Lilly's global network ^[1]. Lilly told Reuters it is "actively engaging with contract manufacturers in India" but did not share further details on which partners or plants are involved ^[1].

The investment covers drugs beyond obesity treatment, including medicines for diabetes, Alzheimer's, cancer and autoimmune conditions ^[1]. But the timing lines up closely with Lilly's push into India's weight-loss market. The company launched Mounjaro, its brand name for tirzepatide, in India this year, and sales of Mounjaro and Novo Nordisk's Wegovy both doubled within months of their respective launches there ^[1]. India is projected to have the world's second-largest obese population by 2050, which has fueled demand ^[1].

Lilly is also building a separate manufacturing and quality facility in Hyderabad that will oversee its contract manufacturing network across India and provide technical support ^[1]. Recruitment for that site will begin immediately, with plans to hire engineers, chemists, analytical scientists and quality control staff ^[1].

The India spending is part of a broader manufacturing buildout. Last month, Lilly announced a separate $5 billion investment in a new facility in Virginia, part of a larger $27 billion plan to build four new U.S. plants over the next five years ^[1]. That U.S. expansion comes as the Trump administration imposed a 100% tariff on imported branded and patented drugs starting October 1, prompting drugmakers to bolster domestic manufacturing ^[1].

Lilly is also bracing for new competition in India. The main patent on semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is set to expire in India next year, and generic drugmakers there are racing to launch cheaper copies ^[1].

Why it matters for patients

For patients in the U.S., this announcement is mainly a signal about where and how Lilly is building capacity to meet global demand for tirzepatide, the active ingredient in Mounjaro and Zepbound. The investment is explicitly framed around serving "price-sensitive markets" like India through local production rather than U.S. manufacturing ^[1]. The sources do not say whether or how this Indian investment will affect U.S. supply, pricing, or availability of Zepbound or Mounjaro. Separately, Lilly's much larger U.S. manufacturing buildout, including the $27 billion plan for four new domestic plants, is more directly tied to supply for the American market and to new tariffs on imported branded drugs ^[1].

Patients should also be aware that generic versions of semaglutide, not tirzepatide, are expected to become available in some markets once patents expire next year, according to the sources, though this specifically concerns India rather than the U.S. market ^[1].

What happens next

Lilly said hiring at its new Hyderabad manufacturing and quality facility would begin immediately as of the October 6 announcement ^[1]. The company did not specify a timeline for when the broader $1 billion investment across contract manufacturers would be completed, or when any resulting capacity would come online ^[1].